Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications f
Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – a
Sanofi has not had the success it was hoping for with its oral BTK inhibitors, acquired as part of its $3.7 billion buyout of Principia Biopharma, but can now point to a w
Novartis' big-selling IgE inhibitor Xolair has been a mainstay of treatment for refractory chronic spontaneous urticaria (CSU) for many years, but its efforts to find a su
Sanofi and Regeneron have reported disappointing results in a trial of Dupixent in people with chronic spontaneous urticaria (CSU) who don't respond to the only approved biologic treatment,
Novartis' big-selling IgE inhibitor Xolair has been a mainstay of treatment for chronic spontaneous urticaria (CSU) for many years, but with biosimilars looming the company has been looking
Oskar Mӧbert, Vice President of OpenData at Veeva Systems, spoke with Ian Cornish, Associate Director of Data Platforms at Astellas, about the company’s decision to opt into Veeva’s OpenDat